Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2021 | Recent updates on pelabresib for myelofibrosis

Prithviraj Bose, MBBS, MD Anderson Cancer Center, Houston, TX, talks on the use of the potentially disease-modifying bromodomain inhibitor, pelabresib, for the treatment of myelofibrosis. Dr Bose sheds light on the ongoing MANIFEST (NCT02158858) and MANIFEST-2 (NCT04603495) trials, in which the combination of pelabresib and the JAK inhibitor ruxolitinib are currently under investigation, as well as commenting on the use of pelabresib in different settings. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.

Disclosures

Prithviraj Bose, MBBS, has received honoraria from Incyte, Celgene, BMS, CTI BioPharma, Sierra Oncology, Novartis, Blueprint Medicines and Kartos; and has received research support from Incyte, Celgene, BMS, CTI BioPharma, Constellation, Kartos, Blueprint Medicines, Astellas, Pfizer, Promedior and NS Pharma.